K182997 is an FDA 510(k) clearance for the enlighten III Laser System. Classified as Powered Laser Surgical Instrument within the GEX classification (a category for powered laser surgical instruments across multiple specialties), Class II - Special Controls.
Submitted by Cutera, Inc. (Brisbane, US). The FDA issued a Cleared decision on December 12, 2018 after a review of 43 days - a notably fast clearance cycle.
This device falls under the General & Plastic Surgery FDA review panel, regulated under 21 CFR 878.4810 - the FDA general and plastic surgery device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.
Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.
View all Cutera, Inc. devices
NCT03284333
Completed
Interventional
Industry-sponsored
enLighten Laser With MLA Handpiece for Treatment of Moderate and Severe Acne Scars
Open-label, Prospective, Multicenter Study to Evaluate the Cutera enLighten™ Laser and a Micro-Lens Array Handpiece Attachment for the Treatment of Moderate and Severe Acne Scars
| Condition studied |
Acne Scars - Mixed Atrophic and Hypertrophic |
| Study design |
Single group |
| Eligibility |
All sexes
· 18 Years+
· Healthy volunteers accepted
|
| Principal investigator |
Stephen Ronan, M.D. |
| Sponsor |
Cutera Inc.
(industry)
|
Started 2017-07-27
→
Primary completion 2018-09-05
Primary outcome
Correct Identification of the 12 Weeks Post-final Treatment Photographs From the Baseline Photographs by at Least 2 of the 3 Blinded Reviewers in 75% of the Patients.
View full study on ClinicalTrials.gov